Medicine and Dentistry
Imatinib
100%
Patient
100%
Chronic Myelogenous Leukemia
80%
Combination Therapy
40%
Nilotinib
40%
Diseases
20%
Phosphotransferase
10%
Point Mutation
10%
Phosphotransferase Inhibitor
10%
Development
10%
Tyrosine-Kinase Inhibitor
10%
Gene Fusion
10%
Enalapril Maleate
10%
Dasatinib
10%
Age
10%
Abelson Kinase
10%
Survival
10%
Disease
10%
Mutant
10%
Stem Cell
10%
Pharmacology, Toxicology and Pharmaceutical Science
Imatinib
100%
Chronic Myeloid Leukemia
80%
Nilotinib
40%
Diseases
20%
Phosphotransferase
10%
Protein Tyrosine Kinase Inhibitor
10%
Enalapril Maleate
10%
Phosphotransferase Inhibitor
10%
Abelson Kinase
10%
Dasatinib
10%
Survival
10%
Neuroscience
Imatinib
100%
Myeloid
80%
Nilotinib
40%
Kinase
20%
Point Mutation
10%
Dasatinib
10%
Abelson Kinase
10%
Gene Fusion
10%
Biochemistry, Genetics and Molecular Biology
Myeloid
80%
Nilotinib
40%
Stem Cell
20%
Kinase
20%
Imatinib
20%
Wild Type
10%
Development
10%
Point Mutation
10%
Dasatinib
10%
Gene Fusion
10%
Age
10%
Survival
10%
Mutant
10%
Spectrum
10%
Nursing and Health Professions
Dasatinib
10%
Abelson Kinase
10%
Phosphotransferase Inhibitor
10%